Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rashad Alsalahi"'
Autor:
Essam A. Ali, Mohamed A. Ibrahim, Muzaffar Iqbal, Rashad Alsalahi, Gamal A. Mostafa, Suliman Al Jarboua
Publikováno v:
Separations, Vol 10, Iss 9, p 474 (2023)
Safinamide is an orally active, selective monoamine oxidase-B inhibitor with dopaminergic and non-dopaminergic properties approved by the European Medicine Agency and US Food and Drug Administration for the treatment of mid- to late-stage fluctuating
Externí odkaz:
https://doaj.org/article/ce100cc88e504d76883a383bd45f6aaf
Publikováno v:
Molecules, Vol 26, Iss 15, p 4663 (2021)
Fostamatinib is a prodrug of the active metabolite tamatinib, which is a spleen tyrosine kinase (Syk) inhibitor used in the treatment of primary chronic adult immune thrombocytopenia and rheumatoid arthritis. A highly sensitive, rapid, reliable, and
Externí odkaz:
https://doaj.org/article/2e09a768360d49ccb553b99839581f8b
Dubermatinib (DMB, TP-0903), a benzenesulfonamide, is an inhibitor of the tyrosine kinase AXL, which is a member of the TAM family, and can prevent GAS6-mediated activation of AXL in cancer cells. Patients with previously treated chronic lymphocytic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6f0f460a3f3d9034e523fbecbb2bbda
https://doi.org/10.20944/preprints202305.1022.v1
https://doi.org/10.20944/preprints202305.1022.v1
Publikováno v:
International Journal of Environmental Analytical Chemistry. :1-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b30ba596b524194c7762ad67a23b70b2
https://doi.org/10.1080/03067319.2022.2045284
https://doi.org/10.1080/03067319.2022.2045284